IN8bio, Inc. – NASDAQ:INAB

Add to watchlist

$2.28

+2.01

+744.44%

Market closed

Open in about 16 hours

-69.24%

month

-69.24%

quarter

-80.99%

year

Market Cap	17.04M
Enterprise value	15.99M

P/E	-1.1
EV/Sales	N/A
EV/EBITDA	-0.39
Price/Sales	N/A
Price/Book	1.24
PEG ratio	0.04
EPS	-0.91

Revenue	N/A
EBITDA	-29.78M
Income	-31.04M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

IN8bio, Inc. (NASDAQ:INAB): Profit margin
Jun 2023	0	-7.71M
Sep 2023	0	-7.16M
Dec 2023	3.74M	-7.59M	-202.72%
Mar 2024	0	-8.56M

IN8bio Financials Estimate

Q Y

IN8bio, Inc. (NASDAQ:INAB): Analyst Estimates
Mar 2024	0	-8.56M
Sep 2025	11.6M	-1.79M	-15.43%
Oct 2025	5.8M	-4.76M	-82.1%
Dec 2025	16M	-4.97M	-31.11%

Analysts Price target
Financials & Ratios estimates

IN8bio, Inc. (NASDAQ:INAB): Earnings per share (EPS)
2023-11-09	-0.25	-0.23
2024-03-14	-0.16	-0.21
2024-05-09	-0.17	-0.2

IN8bio, Inc. (NASDAQ:INAB): Debt to assets
Jun 2023	29718000	7.91M	26.65%
Sep 2023	26208000	8.45M	32.24%
Dec 2023	33709000	8.77M	26.02%
Mar 2024	25549000	8.02M	31.4%

IN8bio, Inc. (NASDAQ:INAB): Cash Flow
Jun 2023	-5.33M	-22K	11.49M
Sep 2023	-5.71M	-77K	1.65M
Dec 2023	-4.85M	-72K	13.35M
Mar 2024	-7.91M	-71K	-277K

IN8bio alternative data

IN8bio, Inc. (NASDAQ:INAB): Employee count
Aug 2023	28
Sep 2023	29
Oct 2023	29
Nov 2023	29
Dec 2023	31
Jan 2024	31
Feb 2024	31
Mar 2024	31
Apr 2024	31
May 2024	31
Jun 2024	31
Jul 2024	34

IN8bio
Hedge Funds Holdings Q1 2023

4.49% -1.09%

of INAB is owned by hedge funds

11 -5

hedge funds hold INAB stock

941.05K -267.55K

shares is hold by hedge funds

INAB hedge funds holdings changes

IN8bio, Inc. (NASDAQ:INAB): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	3445446	0
Oct 2024	8913646	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	4 Oct 2024	KREIS LESLIE W. 10 percent owner 10 percent owner	Pre-Funded Warrants	709,040	N/A	N/A
Purchase	4 Oct 2024	KREIS LESLIE W. 10 percent owner 10 percent owner	Series C Warrant	709,040	$0.27	$191,441
Purchase	4 Oct 2024	FLETCHER AARON G.L. 10 percent owner 10 percent owner	Pre-Funded Warrants	709,040	N/A	N/A
Purchase	4 Oct 2024	FLETCHER AARON G.L. 10 percent owner 10 percent owner	Series C Warrant	709,040	$0.27	$191,441
Purchase	4 Oct 2024	FAIRBAIRN EMILY director director	Series C Warrants (right to buy)	3,038,743	$0.27	$820,461
Purchase	4 Oct 2024	FAIRBAIRN EMILY director director	Pre-Funded Warrants (right to buy)	3,038,743	N/A	N/A
Purchase	13 Dec 2023	KREIS LESLIE W. 10 percent owner 10 percent owner	Pre-Funded Warrants	574,241	N/A	N/A
Purchase	13 Dec 2023	KREIS LESLIE W. 10 percent owner 10 percent owner	Series A Warrant	574,241	$1.25	$717,801
Purchase	13 Dec 2023	KREIS LESLIE W. 10 percent owner 10 percent owner	Series B Warrant	574,241	$1.5	$861,362
Purchase	13 Dec 2023	FLETCHER AARON G.L. 10 percent owner 10 percent owner	Pre-Funded Warrants	574,241	N/A	N/A

IN8bio
Executives

Insider	Age	Since	Compensation
Mr. William Ho (1977) Co-Founder, Pres, Chief Executive Officer & Director	48		$573,170
Dr. Lawrence S. Lamb Ph.D. (1954) Executive Vice President, Co-Founder & Chief Scientific Officer	71		$365,000

IN8bio
Latest News

Tuesday, 10 December 2024
07:00	IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting	globenewswire.com
Tuesday, 12 November 2024
16:26	IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	globenewswire.com
Wednesday, 4 September 2024
16:01	IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia	globenewswire.com
Thursday, 29 August 2024
06:05	IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Monday, 12 August 2024
08:05	IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100	globenewswire.com
Monday, 24 June 2024
08:00	IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference	globenewswire.com
Thursday, 13 June 2024
16:01	IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	globenewswire.com
Monday, 3 June 2024
06:05	IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting	globenewswire.com
Friday, 24 May 2024
08:00	IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024	globenewswire.com
Thursday, 23 May 2024
17:00	IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting	globenewswire.com
Tuesday, 14 May 2024
10:00	IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress	globenewswire.com
Monday, 13 May 2024
08:00	IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024	globenewswire.com
Thursday, 9 May 2024
16:00	IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	globenewswire.com
Tuesday, 30 April 2024
06:05	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	globenewswire.com
Wednesday, 24 April 2024
08:00	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	globenewswire.com
Tuesday, 16 April 2024
16:05	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	GlobeNewsWire
Tuesday, 5 March 2024
16:30	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	GlobeNewsWire
Friday, 10 November 2023
07:00	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting	GlobeNewsWire
Thursday, 2 November 2023
09:17	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting	GlobeNewsWire
Tuesday, 15 August 2023
08:00	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference	GlobeNewsWire
Monday, 5 June 2023
11:10	IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross	Zacks Investment Research
Wednesday, 24 May 2023
13:13	IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know	Zacks Investment Research
Thursday, 4 May 2023
10:46	Best Penny Stocks To Buy Today? 4 To Watch Under $5	PennyStocks
Tuesday, 2 May 2023
13:24	Stock Market Today: Penny Stocks To Watch Amid Banking Crisis	PennyStocks
Wednesday, 26 April 2023
08:30	Why Is IN8bio (INAB) Stock Up 9% Today?	InvestorPlace
Tuesday, 25 April 2023
10:40	IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment	Proactive Investors
09:36	What Is Going on With In8bio (INAB) Stock Today?	InvestorPlace
Tuesday, 11 April 2023
08:00	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting	GlobeNewsWire
Thursday, 16 March 2023
08:00	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023	GlobeNewsWire
Wednesday, 1 March 2023
08:00	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of IN8bio stock today?

One share of IN8bio stock can currently be purchased for approximately $2.28.
When is IN8bio's next earnings date?

Unfortunately, IN8bio's (INAB) next earnings date is currently unknown.
Does IN8bio pay dividends?

No, IN8bio does not pay dividends.
How much money does IN8bio make?

IN8bio has a market capitalization of 17.04M. IN8bio made a loss 30.01M US dollars in net income (profit) last year or -$0.2 on an earnings per share basis.
What is IN8bio's stock symbol?

IN8bio, Inc. is traded on the NASDAQ under the ticker symbol "INAB".
What is IN8bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of IN8bio?

Shares of IN8bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are IN8bio's key executives?
IN8bio's management team includes the following people:
- Mr. William Ho Co-Founder, Pres, Chief Executive Officer & Director(age: 48, pay: $573,170)
- Dr. Lawrence S. Lamb Ph.D. Executive Vice President, Co-Founder & Chief Scientific Officer(age: 71, pay: $365,000)
Is IN8bio founder-led company?

Yes, IN8bio is a company led by its founders Mr. William Ho and Dr. Lawrence S. Lamb Ph.D..
How many employees does IN8bio have?

As Jul 2024, IN8bio employs 34 workers, which is 10% more then previous month and 10% more then previous quarter.
When IN8bio went public?

IN8bio, Inc. is publicly traded company for more then 4 years since IPO on 30 Jul 2021.
What is IN8bio's official website?

The official website for IN8bio is in8bio.com.
Where are IN8bio's headquarters?

IN8bio is headquartered at 350 5th Avenue, New York, NY.
How can i contact IN8bio?

IN8bio's mailing address is 350 5th Avenue, New York, NY and company can be reached via phone at +64 6 600 6438.

IN8bio, Inc.

in8bio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

+64 6 600 6438

350 5th Avenue
New York, NY 10118

CIK: 0001740279
ISIN: US45674E1091
CUSIP: 45674E109